Recent Company News

• 01:26 PM ET Nov 14, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 16-Nov

• 08:54 AM ET Nov 14, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:37 AM ET Nov 14, 2025
  

  EMA CHMP publishes summary of opinions for November 2025 meeting

• 07:03 AM ET Nov 14, 2025
  

  Ionis Pharmaceuticals issues press release regarding previous CHMP positive opinion of DAWNZERA (donidalorsen) ($69.84, 0.00)

• 06:34 AM ET Nov 14, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Dawnzera (¥8366.0000, 0)

• 06:45 PM ET Nov 09, 2025
  

  Otsuka Holdings presents 12-month interim data from phase 3 of Sibeprenlimab for treatment of IgAN at 2025 ASN (¥8370.0000, 0)

• 02:20 PM ET Nov 07, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 9-Nov

• 08:07 AM ET Nov 06, 2025
  

  Ionis presents new long-term data on DAWNZERA at ACAAI 2025 Annual Meeting ($74.68, 0.00)

• 01:05 AM ET Nov 06, 2025
  

  Otsuka Holdings doses first participants in Phase 3 clinical trial evaluating quabodepistat (¥8475.0000, +37)

• 01:42 PM ET Oct 31, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 2-Nov